Higher expression of XPF is a critical factor in intrinsic chemotherapy resistance of human renal cell carcinoma
Open Access
- 20 August 2016
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 139 (12) , 2827-2837
Abstract
Human renal cancer is extremely resistant to chemotherapy and radiation therapy. This clinical characteristic reduces the efficacy of chemotherapeutic agents in the treatment of recurrence or metastasis following surgical resection. Understanding the mechanism of chemotherapy resistance in renal cell carcinoma remains a significant challenge. In this study, we have shown that varied level of XPF expression was organ‐tissue specific by comparing human renal cancer, bladder cancer, testicular cancer and their normal tissue counterparts, respectively. The expression of XPF was significantly higher in renal cancer than in bladder cancer and testicular cancer and correlated with the clinical characteristic of their chemotherapeutics sensitivity. These novel findings proposed that the intrinsic chemoresistance of human renal cell carcinomas might be derived from the high level of XPF expression. In a panel of five cancer cell lines, decreasing cisplatin sensitivity correlated with increasing levels of XPF expression. Knockdown of XPF expression not only increased sensitivity of renal carcinoma cells to cisplatin treatment by affecting the DNA damage response, including DNA repair, cell cycle regulation and apoptosis, but also increased senescence of renal cancer cell. Furthermore, experiment in vivo confirmed that silenced XPF significantly increased the sensitivity and survival following treatment with cisplatin in xenograft mice bearing renal cell tumor. These findings firstly uncover a partial mechanism of intrinsic chemoresistance in renal cancer and may provide a new approach to break through the obstacle of intrinsic chemoresistance by targeting the XPF protein with a potential new inhibitor.Keywords
Funding Information
- National Natural Science Foundation of China (81172441)
This publication has 37 references indexed in Scilit:
- DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapyNucleic Acids Research, 2012
- Multiple DNA Binding Domains Mediate the Function of the ERCC1-XPF Protein in Nucleotide Excision RepairJournal of Biological Chemistry, 2012
- Defective transcription initiation causes postnatal growth failure in a mouse model of nucleotide excision repair (NER) progeriaProceedings of the National Academy of Sciences, 2012
- Physiological consequences of defects in ERCC1–XPF DNA repair endonucleaseDNA Repair, 2011
- Role of Endonucleases XPF and XPG in Nucleotide Excision Repair of Platinated DNA and Cisplatin/Oxaliplatin CytotoxicityChemBioChem, 2011
- Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA DamageMolecular Cell, 2009
- Elevated Glutathione Levels Confer Cellular Sensitization to Cisplatin Toxicity by Up-Regulation of Copper Transporter hCtr1Molecular Pharmacology, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell linesInternational Journal of Cancer, 2004
- Purification and Characterization of the XPF-ERCC1 Complex of Human DNA Repair Excision NucleaseJournal of Biological Chemistry, 1995